Pegloticase - Hyperuricaemia and Gout

You are here : Home > Formulary Search > Pegloticase - Hyperuricaemia and Gout

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NFD1

Restrictions / Comments :

Documentation

Policy Statement

Pegloticase - Policy statement PCN 366-2018 - Sep 2018

PAD Profile

ChemicalSubstance :

Pegloticase

Indication :

Hyperuricaemia and Gout

Group Name :

Keywords :

Brand Names Include :

Krystexxa

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Pegloticase is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Hyperuricaemia and Gout.

Committee Recommendations (2)

05 Sep 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Prescribing Clinical Network does not recommend the use of pegloticase for treating severe debilitating chronic tophaceous gout, as its marketing authorisation has been withdrawn in the UK/EU.

See Pegloticase policy statement below for further details

31 Jul 13 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Not recommended for use by NICE guidance TA291. See attached NICE guidance for further information